Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

83.94EUR
11:36am EDT
Change (% chg)

€0.47 (+0.56%)
Prev Close
€83.47
Open
€83.90
Day's High
€84.00
Day's Low
€83.12
Volume
1,733,029
Avg. Vol
2,509,945
52-wk High
€84.00
52-wk Low
€62.50

Select another date:

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies.

UPDATE 3-FDA approves Regeneron, Sanofi $37,000 per year eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies.

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent

* Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis

BRIEF-U.S. list price for Sanofi, Regeneron's Dupixent $37,000

* Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: (Reporting by Ben Hirschler)

FDA approves Regeneron, Sanofi eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON, March 23 Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

Select another date:

More From Around the Web